奇异变形杆菌的临床流行病学和β-内酰胺类药物耐药机制研究进展  

Research progress in clinical epidemiology andβ-lactam resistance mechanism of Proteus mirabilis

作　　者：张彬瑶 马瑞瑞 徐英春[1] 刘亚丽[1] Zhang Binyao;Ma Ruirui;Xu Yingchun;Liu Yali(Department of Clinical Laboratory,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Science,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院检验科,北京100730

出　　处：《中华微生物学和免疫学杂志》2024年第10期906-911,共6页Chinese Journal of Microbiology and Immunology

摘　　要：奇异变形杆菌是一种革兰阴性杆菌,可引起尿路感染、血流感染、消化道感染等,尤其是奇异变形杆菌导致的尿路感染,不仅给临床治疗带来诸多困扰,还会造成严重的公共卫生问题。随着临床治疗抗微生物药物的使用,奇异变形杆菌对β-内酰胺类和喹诺酮类药物的耐药性逐年增加。加上抗微生物药物的不规范使用,耐多药奇异变形杆菌和耐碳青霉烯类药物的奇异变形杆菌相继出现。本文主要对奇异变形杆菌与临床感染、流行病学以及β-内酰胺类耐药机制等进行阐述,为探究奇异变形杆菌新的治疗策略及预防提供思路。Proteus mirabilis is a gram-negative rod-shaped bacterium that can cause urinary tract infections,bloodstream infections and gastrointestinal infections.Urinary tract infections caused by Proteus mirabilis are hard to be treated and pose a serious public health problem.With the use of antimicrobial drugs for clinical treatment,the resistance rates of Proteus mirabilis toβ-lactams and quinolones increase.Besides the unregulated use of antimicrobial drugs contributes to the emergence of multidrug-resistant Proteus mirabilis and carbapenem-resistant Proteus mirabilis.In this review,we will discuss Proteus mirabilis-related clinical infections,and the epidemiological characteristics andβ-lactam resistance mechanism,hoping to provide ideas for the treatment and prevention of Proteus mirabilis infections in the future.

关 键 词：奇异变形杆菌 尿路感染 血流感染 Β-内酰胺酶 耐药机制 

分 类 号：R446.5[医药卫生—诊断学]